Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997092

SCHEMBL21997092

SCHEMBL21997092

CN(C(=O)OC(C)(C)C)C1CC(N)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.43
▸ ASGR1 P07306 1/20 0.36
▸ PIK3R1 P27986 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ AURKA O14965 1/20 0.32
▸ PDPK1 O15530 1/20 0.32
▸ AURKB Q96GD4 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ CHRM3 P20309 1/20 0.32
▸ KDM4D Q6B0I6 1/20 0.31
▸ BUB1 O43683 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ HDAC1 Q13547 1/20 0.30
▸ HDAC2 Q92769 1/20 0.30
▸ HDAC6 Q9UBN7 1/20 0.30
▸ KAT6A Q92794 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18687576 1.00 HSD11B1 (0.43) HSD11B1ASGR1PIK3R1PIK3CAAURKA
SCHEMBL14805518 1.00 HSD11B1 (0.43) HSD11B1ASGR1PIK3R1PIK3CAAURKA
SCHEMBL12731680 0.88 HSD11B1 (0.43) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL22084597 0.88 HSD11B1 (0.43) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL12731681 0.88 HSD11B1 (0.43) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL21541517 0.86 HSD11B1 (0.42) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL29255500 0.86 HSD11B1 (0.42) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL15236700 0.84 HSD11B1 (0.42) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL66374 0.84 HSD11B1 (0.42) HSD11B1ASGR1CHRM2CHRM1CHRM3
SCHEMBL84597 0.84 HSD11B1 (0.42) HSD11B1ASGR1CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 — — EP disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 — — EP disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
CN-116867758-A IRAK degradation agents and uses thereof 凯麦拉医疗公司 2023-10-10 — — CN disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2021127303-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2021-06-24 — — WO disclosed
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives EVOTEC (UK) LTD (GB) 2020-12-24 — — US disclosed
CN-112105357-A Pharmaceutically acceptable 6,5 heterobicyclic derivatives UCB生物制药有限责任公司 2020-12-18 — — CN disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives STING1, IRF3, NFATC1 HSD11B1 1156/4885ASGR1 1092/4885PIK3R1 116/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885ASGR1 2610/4885PIK3R1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.